Exhibit 10.14
AMENDED AND RESTATED
 
RETENTION AND NON-COMPETITION AGREEMENT
 
A.P. Pharma, Inc. (the “Company” or “APP”), and Michael P.J. O’Connell
(“Executive”) entered into a Retention and Non-Competition Agreement (the
“Retention Agreement”), effective the 23rd day of March, 2005 (the “Effective
Date”) in full substitution for the Retention and Non-Competition Agreement
originally entered into between the parties effective May 12, 1999 and amended
in its entirety effective August 1, 2000.  The Retention Agreement is hereby
revised, effective August 23, 2007, so as to fully comply with the applicable
provisions of Section 409A of the Internal Revenue Code of 1986, as amended, and
the final treasury regulations and any guidance promulgated thereunder (“Section
409A”). The rights and obligations of Executive and the Company remain in full
force and effect as set forth below.
 
WHEREAS, the Company desires to retain the services of Executive as set forth in
this Agreement and Executive desires to provide services to the Company, upon
the terms and conditions set forth herein; and
 
WHEREAS, the Company desires to ensure that Executive does not compete with and
is available to provide services to the Company for the period of time set forth
herein;
 
NOW, THEREFORE, in consideration of the covenants and agreements hereinafter set
forth, the parties hereto agree as follows:
 
1.  Term of Agreement.  This Agreement shall commence on the Effective Date and
shall end on (i) December 31, 2006, and shall be automatically renewed for
additional one-year periods without any action required of either party unless
not later than four months prior to the end of any calendar year either party
gives to the other party notice in writing that it intends to terminate the
Agreement at the end of the calendar year.  The Company and Executive agree that
this Agreement shall govern the terms and conditions of Executive’s provision of
services to the Company during the term of this Agreement.
 
2.  Title and Responsibilities.  From and after the Effective Date until the
commencement of any Supplemental  Employment Term (as defined in Section 6 of
this Agreement) (the  “CEO Employment Period”), the Company shall employ
Executive as the President and Chief Executive Officer of the Company reporting
to the Board of Directors.  As President and Chief Executive Officer of the
Company, Executive shall have the duties and responsibilities customarily
associated with such position and as determined from time to time by the Board
of Directors of the Company.  It is understood and agreed that Executive will be
considered an employee of the Company for tax withholding purposes for the
duration of both the CEO Employment Period and the Supplemental Employment
Term.  Executive acknowledges that as a supplemental Employee he shall not have
the power to bind the Company.
 
3.  Obligations.  Executive agrees, during the CEO Employment Period, not to
actively engage in any other employment, occupation or consulting activity for
any direct or indirect remuneration without the prior approval of the Board;
provided, however, that Executive may serve in any capacity with any civic,
educational, or charitable organization.
 
4.  Employee Benefits.  During the CEO Employment Period and Supplemental
Employment Period, Executive shall be eligible to participate in (i) all
employee benefit plans currently and hereafter maintained by the Company for
senior management according to their terms, and (ii) such other employee
benefits as are set forth in this Agreement.
 
5.  CEO Employment Period Compensation.
 
(a)  Base Salary.  During the CEO Employment Period, and during certain
Supplemental Employment Terms, as specified in Section 6 hereof, the Company
shall pay Executive as compensation for his services a base salary at an initial
annualized rate recommended by the Compensation Committee of the Board and
approved by the Board (which rate shall in no event be less than Executive’s
base salary on the Effective Date as adjusted from time to time by the Board or
its Compensation Committee (the “Base Salary”).  The Base Salary shall be paid
periodically in accordance with normal Company payroll practices and subject to
the usual required withholding.  Notwithstanding the foregoing, during the CEO
Employment Period, Executive’s Base Salary shall be reviewed annually for
possible adjustments in light of Executive’s performance of his duties, as
determined by the Board or its Compensation Committee.
 
(b)  Bonus.  During the CEO Employment Period and during Supplemental Employment
Terms as specified in Section 6 hereof, Executive shall be eligible to receive
bonuses as determined by the Board or its Compensation Committee.
 
6.   Transition to Supplemental Employment.
 
(a)  Supplemental Employment Term Definition; Obligations.  The periods of
employment specified in this Section 6 shall be defined as the “Supplemental
Employment Term” for the purposes of this Agreement.  During any Supplemental
Employment Term, Executive shall be required to devote such time in rendering
services to the Company as shall be reasonably agreed upon and acceptable to the
Executive and the Company.  During the Supplemental Employment Term, Executive
shall be free to serve as a director, employee, consultant or advisor to any
other corporation or other business enterprise without the prior written consent
of the Company so long as such activities do not interfere with his duties and
obligations under this Agreement, including without limitation, Executive’s
obligations under Section 8 hereof.  In consideration of Executive’s not working
for a “Drug Delivery Company” (as such term is defined in Section 8) and being
available to provide the mutually agreed upon services required hereunder during
the Supplemental Employment Term, the Executive shall receive the compensation
specified in this Section 6.
 
(b)  Termination of CEO Employment for Cause.  The Company may at any time
terminate Executive’s employment hereunder for “Cause.”  For the purposes of
this Agreement, “Cause” shall mean (i) Executive’s gross negligence or willful
misconduct in connection with the performance of his duties, (ii) Executive’s
conviction of, or plea of nolo contendere to, any felony in a court of competent
jurisdiction, or (iii) Executive’s embezzlement or misappropriation of Company
property.
 
(c)  Termination of CEO Employment by Company Other than for Cause.  If the
Company desires to terminate Executive’s CEO employment with the Company other
than for Cause, then the Company shall provide Executive with written notice of
such termination.  If the Executive’s CEO employment is terminated by the
Company other than for Cause, then, subject to Executive entering into a
Release, the Executive shall remain employed by the Company as a supplemental
employee for a period of 24 months from the date upon which the Executive is
given such written notice from the Company, after which period Executive’s
employment with the Company shall terminate.
 
In connection with the Supplemental Employment Term arising in connection with
termination of Executive’s CEO employment by Company other than for Cause,
Executive shall be paid (i) Base Salary, payable 50% at time of commencement of
Supplemental Employment and the balance in accordance with the Company’s normal
payroll practices and (ii) an annual bonus for the 24-month period (prorated for
any partial year) equal to the bonus paid to Executive during the immediately
preceding 12-month period.
 
(d)  Voluntary Termination of CEO Employment by Executive for Good Reason.  If
Executive desires to voluntarily terminate his CEO employment with the Company
for Good Reason, then Executive shall provide the Company with written notice of
such termination within ninety (90) days of the occurrence of the event that
provides Good Reason under this Agreement, provided however that Executive shall
provide the Company the opportunity to remedy the event within 30 days after
receipt of notice thereof given by the Executive.  Subject to Executive entering
into a release in usual form of the Company and its directors and officers, the
Executive shall remain employed by the Company as a supplemental employee for a
period of 24 months from the date upon which the Company is given such written
notice from Executive, after which period Executive’s employment with the
Company shall terminate.  For the purposes of this Agreement, “Good Reason”
shall mean, during the CEO Employment Period, the occurrence of one of the
following events without the prior written consent of Executive: (i) a material
reduction in Executive’s authority or responsibility which (x) is inconsistent
with his position and/or title with the Company, or (y) diminishes or changes
the Executive’s substantive authority or responsibility relative to Executive’s
authority and responsibility immediately prior to such reduction, (ii) a
material reduction in Executive’s Base Salary (a reduction of more than ten
percent (10%) in any one year), (iii) a material reduction in the kind or level
of employee benefits to which the Executive is entitled which is different from
the level of benefits to which other similar employees are entitled or any
action taken that materially and adversely affects the Executive’s participation
in any employee benefit plan on a basis different from that applicable to other
employees of similar rank, or (iv) Executive’s notification in writing from the
Company that his principal place of work will be relocated by a distance of
40 miles or more from the Company’s present headquarters.
 
The Parties acknowledge that Executive has recently been on a medical leave of
absence from his position as President and Chief Executive Officer of the
Company.  For the avoidance of doubt, if at such time as Executive is ready and
able to assume all of the duties and responsibilities of the position of
President and Chief Executive Officer of the Company, the Company does not
return him to that position, such action shall constitute Good Reason under this
Agreement.
 
In connection with the Supplemental Employment Term arising in connection with a
termination of employment by the Executive for Good Reason, Executive shall be
paid (i) Base Salary for the 24-month period, payable 50% at time of
commencement of Supplemental Employment and the balance in equal installments in
accordance with the Company’s normal payroll practices and (ii) an annual bonus
for the 24-month period (prorated for any partial year) equal to the bonus paid
to Executive during the immediately preceding 12-month period.
 
(e)  Stock Option Vesting During Supplemental Employment Term or upon Change of
Control.
 
(i)  During any Supplemental Employment Term provided for in this Agreement,
stock options that were granted to Executive by the Company (“Options”) shall
continue to vest in accordance with the terms and conditions of the original
option agreements relating to such Options.
 
(ii)  Upon a Change of Control of the Company followed by termination of the
Executive’s employment by the Company without Cause or by the Executive for Good
Reason, all outstanding stock options previously granted to Executive shall
become 100% vested.
 
(f)  Lapse of Restrictions on Restricted Stock.  Upon a Change in Control
provided for in this Agreement, all forfeiture and transfer restrictions on
shares of restricted stock awarded to Executive by the Company (“Restricted
Stock”) shall lapse in accordance with the terms and conditions of the original
restricted stock award agreements relating to such Restricted Stock.
 
(g)  For purposes of this Agreement, “Change of Control”: shall be deemed to
have occurred if (i) any person or group (within the meaning of Rule 13d-3 of
the rules and regulations promulgated under the Securities Exchange Act of 1934,
as amended) shall acquire, in one or a series of transactions, whether through
sale of stock or merger, ownership of stock of APP that possesses fifty percent
or more of the total fair market value or total voting power of the stock of APP
or any successor to APP; (ii) a merger in which APP is a party after which
merger the stockholders of APP immediately before the sale do not retain,
directly or indirectly, at least a majority of the beneficial interest in the
voting stock of the surviving company; or (iii) the sale, exchange or transfer
of all or substantially all of APP’s assets (other than a sale, exchange or
transfer to one or more corporations where the stockholders of APP immediately
before and after such sale, exchange or transfer, directly or indirectly, are
the beneficial owners of at least a majority of the voting stock of the
corporation(s) to which the assets were transferred).
 
7.  Termination of Employment Relationship.  Executive’s supplemental employment
relationship with the Company may not be terminated by the Company prior to the
end of the Supplemental Employment Term, except by written agreement between
both of the parties hereto; provided, however, that Executive’s employment with
the Company, shall immediately and automatically terminate upon Executive’s
breach of Section 8 hereof or for Cause.  No additional benefits or payments
will become payable to Executive hereunder upon a termination
 
8.  Covenant Not to Compete.
 
(a)  Covenant Not to Compete.  During the CEO Employment Period and the
Supplemental Employment Term, Executive will not render services as an employee
or as a consultant providing more than an average of 20 hours per month, or
participate as more than a 5% owner in, any Drug Delivery Company in the
Restricted Territory, as such terms are defined immediately below.
 
(b)  Drug Delivery Company.  “Drug Delivery Company” shall mean each company
listed on Exhibit A hereto so long as such company is engaged in the development
or application of drug delivery technology.  For purposes of this definition,
“drug delivery technology” shall mean technology designed to deliver
pharmacologically active substances into an organism in a manner that is
controlled as to time and/or location of release as compared with bolus
injections or standard oral nasal or rectal dosage forms.  In no event shall
delivery of genetic materials be considered delivery for purposes of this
Section 8.
 
(c)  Restricted Territory.  “Restricted Territory” means any county in the State
of California, each state in the United States and each country in the world.
 
9.  Assignment.  Executive’s rights and obligations under this Agreement shall
not be assignable by Executive.  The Company’s rights and obligations under this
Agreement shall not be assignable by the Company except as incident to the
transfer, by merger, liquidation, or otherwise, of all or substantially all of
the business of the Company.
 
10.  Notices.  Any notice required or permitted under this Agreement shall be
given in writing and shall be deemed to have been effectively made or given if
personally delivered, or if sent by facsimile, or mailed or sent via overnight
courier to the other party at its address may designate by written notice to the
other party hereto.  Any effective notice hereunder shall be deemed given on the
date personally delivered or on the date sent by facsimile or deposited in the
United States mail (sent by certified mail, return receipt requested), as the
case may be, at the following addresses:
 
(i)  If to the Company:
 
 
A.P.  Pharma, Inc.

 
123 Saginaw Drive

 
Redwood City, California 94063

 
Attn: Chairman of the Board

 
(ii)  If to the Executive:
 
 
Michael P.J. O’Connell

 
13621 Pierce Road

 
Saratoga, California 95070

 
11.  Arbitration.  The parties hereto agree that any dispute or controversy
arising out of, relating to, or in connection with this Agreement, or the
interpretation, validity, construction, performance, breach, or termination
thereof, shall be finally settled by binding arbitration to be held in San Mateo
County, California under the Employment Dispute Resolution Rules of the American
Arbitration Association as then in effect (the “Rules”).  The arbitrator(s) may
grant injunctions or other relief in such dispute or controversy.  The decision
of the arbitrator(s) shall be final, conclusive and binding on the parties to
the arbitration, and judgment may be entered on the decision of the
arbitrator(s) in any court having jurisdiction.
 
The arbitrator(s) shall apply California law to the merits of any dispute or
claim, without reference to rules of conflicts of law, and the arbitration
proceedings shall be governed by federal arbitration law and by the Rules,
without reference to state arbitration law.
 
The parties shall each pay one-half of the costs and expenses of such
arbitration, and each party shall pay its own counsel fees and expense.
 
EXECUTIVE HAS READ AND UNDERSTANDS THIS SECTION 12, WHICH DISCUSSES
ARBITRATION.  EXECUTIVE UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, EXECUTIVE
AGREES TO SUBMIT ANY CLAIMS ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH
THIS AGREEMENT, OR THE INTERPRETATION, VALIDITY, CONSTRUCTION, PERFORMANCE,
BREACH OR TERMINATION THEREOF TO BINDING ARBITRATION, AND THAT THIS ARBITRATION
CLAUSE CONSTITUTES A WAIVER OF EXECUTIVE’S RIGHT TO A JURY TRIAL AND RELATES TO
THE RESOLUTION OF ALL DISPUTES RELATING TO EXECUTIVE’S EMPLOYMENT RELATIONSHIP
WITH THE COMPANY.
 
12.  Withholding.  The Company shall be entitled to withhold, or cause to be
withheld, from payment any amount of withholding taxes required by law with
respect to payments made to Executive in connection with his employment
hereunder.
 
13.      Section 409A.
 
(a)           Distributions.  Notwithstanding anything to the contrary in this
Agreement, if Executive is a “specified employee” within the meaning of Section
409A  at the time of Executive’s termination of CEO Employment, and the benefits
payable to Executive, if any, pursuant to this Agreement, when considered
together with any other payments or separation benefits which may be considered
deferred compensation under Section 409A (together, the “Deferred Compensation
Separation Benefits”) will not and could not under any circumstances, regardless
of when such termination occurs, be paid in full by March 15 of the year
following Executive’s termination, then only that portion of the Deferred
Compensation Separation Benefits which do not exceed the Section 409A Limit (as
defined below) may be made within the first six (6) months following Employee’s
termination of employment in accordance with the payment schedule applicable to
each payment or benefit. For these purposes, each severance payment is hereby
designated as a separate payment and will not collectively be treated as a
single payment.  Any portion of the Deferred Compensation Separation Benefits in
excess of the Section 409A Limit shall accrue and, to the extent such portion of
the Deferred Compensation Separation Benefits would otherwise have been payable
within the first six (6) months following Executive’s termination of CEO
employment, will become payable on the first payroll date that occurs on or
after the date six (6) months and one (1) day following the date of Executive’s
termination of CEO employment.  All subsequent Deferred Compensation Separation
Benefits, if any, will be payable in accordance with the payment schedule
applicable to each payment or benefit.
 
(b)           Amendment.  This provision is intended to comply with the
requirements of Section 409A so that none of the payments and separation
benefits to be provided hereunder will be subject to the additional tax imposed
under Section 409A, and any ambiguities herein will be interpreted to so
comply.  The Company and Executive agree to work together in good faith to
consider amendments to this Agreement and to take such reasonable actions which
are necessary, appropriate or desirable to avoid imposition of any additional
tax or income recognition prior to actual payment to Executive under Section
409A.
 
(c)           Section 409A Limit.  For purposes of this Agreement, “Section 409A
Limit” will mean the lesser of two (2) times: (i) Executive’s annualized
compensation based upon the annual rate of pay paid to Executive during the
Company’s taxable year preceding the Company’s taxable year of Executive’s
termination of Full-Time employment as determined under Treasury Regulation
1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with
respect thereto; or (ii) the maximum amount that may be taken into account under
a qualified plan pursuant to Section 401(a)(17) of the Code for the year in
which Executive’s Full-Time employment is terminated.
 
      14.          Severability.  If any term or provision of this Agreement
shall to any extent be declared illegal or unenforceable by arbitrator(s) or by
a duly authorized court of competent jurisdiction, then the remainder of this
Agreement or the application of such term or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be
affected thereby, each term and provision of this Agreement shall be valid and
enforceable to the fullest extent permitted by law and the illegal or
unenforceable term or provision shall be deemed replaced by a term or provision
that is valid and enforceable and that comes to expressing the intention of the
invalid or unenforceable term of provision.
 
15.           Entire Agreement.  This Agreement and the agreements relating to
the Options and Restricted Stock represent the entire agreement of the parties
with respect to the matters set forth herein, and to the extent inconsistent
with other prior contracts, arrangements or understandings between the parties,
supersedes all such previous contracts, arrangements or understandings between
the Company and the Executive.  The Agreement may be amended at any time only by
mutual written agreement signed by the parties hereto.
 
16.           Headings.  The headings of sections herein are included solely for
convenience of reference and shall not control the meaning or interpretation of
any of the provisions of this Agreement.
 
17.           Counterparts.  This Agreement may be executed by either of the
parties hereto in counterparts, each of which shall be deemed to be an original,
but all such counterparts shall together constitute one and the same instrument.
 
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year first above written.
 
EXECUTIVE
A.P. Pharma, Inc.
     
By:                                                          
 
Name:                                                                
Name:                                                          
 
 
Title:                                                          

 

--------------------------------------------------------------------------------

EXHIBIT A
 
3M Pharmaceuticals
 
Alcon
 
Alkermes, Inc.
 
Alza Corporation
 
Andrx Corporation
 
Aradigm Corporation
 
Biovail Corporation International
 
Cardinal Health
 
Cima Labs, Inc.
 
Dura Pharmaceuticals, Inc.
 
Durect Corporation
 
Eurand
 
Faulding Inc.
 
Inhale Therapeutic Systems, Inc.
 
K-V Pharmaceutical Company
 
Lohmann Therapie Systeme GmbH
 
Noven Pharmaceuticals, Inc.
 
Penwest Pharmaceuticals Co.
 
Research Triangle Pharmaceuticals
 
SkyePharma plc
 
Teva Pharmaceuticals
 
Watson Pharmaceuticals, Inc.
 
Yamanouchi Pharmaceutical Co., Ltd.
 
1.  Including any and all successors and divisions or subsidiaries of such
Persons.
 

--------------------------------------------------------------------------------